Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis
Francesca D'Addio,Francesca D'Addio,Alessandro Valderrama Vasquez,Moufida Ben Nasr,Edward Franek,Dalong Zhu,Lirong Li,Guang Ning,Emilian Snarski,Paolo Fiorina,Paolo Fiorina +10 more
TL;DR: This study suggests the following: 1) that remission of T1D is possible by combining HSC transplantation and immunosuppression; 2) that autologous nonmyeloablative H SC transplantation represents an effective treatment for selected individuals with T2D; and 3) that safer HSC-based therapeutic options are required.
read more
Abstract: Type 1 diabetes (T1D) is one of the major autoimmune diseases affecting children and young adults worldwide. To date, the different immunotherapies tested have achieved insulin independence in 1c levels and an increase in C-peptide levels compared with pretreatment. Despite a complete immune system recovery (i.e., leukocyte count) after treatment, 52% of treated individuals experienced adverse effects. Our study suggests the following: 1 ) that remission of T1D is possible by combining HSC transplantation and immunosuppression; 2 ) that autologous nonmyeloablative HSC transplantation represents an effective treatment for selected individuals with T1D; and 3 ) that safer HSC-based therapeutic options are required.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Diabetes mellitus as a poor mobilizer condition.
TL;DR: This review summarizes the current experimental and clinical evidence that diabetes mellitus is a risk factor for poor mobilization of HSCs and indicates that hyperglycemia hampers regulation of CXCL12 and clinical studies suggest that diabetes impairs HSC mobilization.
T Cell Receptor Profiling in Type 1 Diabetes.
TL;DR: The genetic susceptibility and dominant protection for type 1 diabetes (T1D) associated with human leukocyte antigen (HLA) haplotypes, along with minor risk variants, have long been thought to shape the T cell receptor (TCR) repertoire and eventual phenotype of autoreactive T cells that mediate β-cell destruction.
Additional file 2 of One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study
Lü Jing,Ling, Qing,Wang Bin,LI Li-rong,Zhang Wei,Bi Yan,Zhu Da-long +6 more
- 11 Jun 2021
TL;DR: This study presents 1-year β cell function changes in type 1 diabetes patients receiving allogeneic umbilical cord mesenchymal stromal cells, with data stratified by diabetic ketosis and diabetic ketoacidosis history, showing absolute and percent changes.
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Michael J. Haller,Stephen E. Gitelman,Peter A. Gottlieb,Aaron W. Michels,Daniel J. Perry,Andrew R Schultz,Maigan A. Hulme,Jonathan J. Shuster,Baiming Zou,Clive Wasserfall,Amanda L. Posgai,Clayton E. Mathews,Todd M. Brusko,Mark A. Atkinson,Desmond A. Schatz +14 more
TL;DR: A phase II study of ATG+G-CSF in patients with new-onset type 1 diabetes is ongoing and may support ATG- CSF as a prevention strategy in high-risk subjects.
Immunomodulation effect of mesenchymal stem cells in islet transplantation
TL;DR: In this article, a review highlights the interactions between mesenchymal stem cells and different immune cells to mediate immunomodulatory functions along with the importance of MSCs therapy for the successful islet transplantation.
References
Type 1 Diabetes
TL;DR: Current progress in epidemiology, pathology, diagnosis, and treatment of type 1 diabetes, and prospects for an improved future for individuals with this disease are discussed.
2.3K
Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study
TL;DR: If present trends continue, doubling of new cases of type 1 diabetes in European children younger than 5 years is predicted between 2005 and 2020, and prevalent cases younger than 15 years will rise by 70%.
1.8K
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
Tihamer Orban,Brian N. Bundy,Dorothy J. Becker,Linda A. DiMeglio,Stephen E. Gitelman,Robin Goland,Peter A. Gottlieb,Carla J. Greenbaum,Jennifer B. Marks,Roshanak Monzavi,Antoinette Moran,Philip Raskin,Henry Rodriguez,William E. Russell,Desmond A. Schatz,Diane K. Wherrett,Darrell M. Wilson,Jeffrey P. Krischer,Jay S. Skyler +18 more
TL;DR: Abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years.
516
Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.
Nicole A. Sherry,William Hagopian,Johnny Ludvigsson,Sunil M Jain,Jack Wahlen,Robert J. Ferry,Bruce W. Bode,S. Aronoff,Christopher Holland,David Carlin,Karen L King,Ronald L. Wilder,Stanley R. Pillemer,Ezio Bonvini,Syd Johnson,Kathryn E. Stein,Scott Koenig,Kevan C. Herold,Anastasia G. Daifotis +18 more
TL;DR: It is suggested that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in β-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.
473
Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture.
Nurit Rachamim,Judith Gan,Harry Segall,Rita Krauthgamer,Hadar Marcus,Alain Berrebi,Massimo F. Martelli,Yair Reisner +7 more
TL;DR: It is possible, that CD34+ cells in the megadose transplants-perhaps by their inability to provide costimulatory molecules-are actively reducing the frequency of CTL-p directed against their antigens, and thereby help to overcome allogeneic rejection, and enhance their own engraftment.
195
Related Papers (5)
Nicole A. Sherry,William Hagopian,Johnny Ludvigsson,Sunil M Jain,Jack Wahlen,Robert J. Ferry,Bruce W. Bode,S. Aronoff,Christopher Holland,David Carlin,Karen L King,Ronald L. Wilder,Stanley R. Pillemer,Ezio Bonvini,Syd Johnson,Kathryn E. Stein,Scott Koenig,Kevan C. Herold,Anastasia G. Daifotis +18 more
Bart Keymeulen,Evy Vandemeulebroucke,Anette-G. Ziegler,Chantal Mathieu,Leonard Kaufman,Geoff Hale,Frans Gorus,Michel Goldman,M Walter,Sophie Candon,Liliane Schandené,Laurent Crenier,Christophe De Block,Jean-Marie Seigneurin,Pieter De Pauw,Denis Pierard,Ilse Weets,Peppy Rebello,Pru Bird,Eleanor Berrie,Mark Frewin,Herman Waldmann,Jean-François Bach,Daniel Pipeleers,Lucienne Chatenoud +24 more